Key result
Immune responses may act as second hits to trigger Moyamoya disease in genetically susceptible individuals.
Why the study?
The etiology of Moyamoya disease is unknown, and the role of immune-related responses as triggers in genetically susceptible individuals is emerging but not fully understood.
This review highlights the emerging role of immune-related responses as a necessary 'second hit' for the onset of Moyamoya disease in genetically susceptible individuals.
Moyamoya disease (MMD) is a rare cerebrovascular disorder with unknown etiology. MMD is characterized by progressive narrowing of arteries of the brain and the formation of a compensatory network of fragile vessels. Genetic studies have identified RNF213, also known as mysterin, as a susceptibility gene for MMD, but the low penetrance in genetically susceptible individuals suggests that a second hit is necessary to trigger disease onset. Recently, several molecular studies uncovered RNF213 as a key antimicrobial protein with important functions in the immune system. In addition, an increasing number of clinical reports describe the development of moyamoya angiopathy (MMA) associated with infection or autoimmune disorders. Together, this growing body of molecular and clinical evidence points towards immune-related responses as second hits to trigger MMD onset.
No takes yet. Share an insight, caveat, or question.
Asselman et al. (2022) conducted a review in Moyamoya disease. Immune-related responses was evaluated. Growing molecular and clinical evidence suggests that immune-related responses act as second hits to trigger Moyamoya disease onset in genetically susceptible individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: